InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,634.61
(
1.15%
)
US TECH 100
19,190.00
(
1.03%
)
Dow Jones
41,175.08
(
1.14%
)
Brent Oil
78.38
(
2.32%
)
Bitcoin
63,798.79
(
5.68%
)
Post# of 72979
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Fox13

Send PM Follow Ignore
Followers 16
Posts 4525
Boards Moderated 0
Alias Born 10/04/2006

Fox13

Re: 3xBuBu post# 55609

Thursday, 05/06/2010 8:29:39 AM

Thursday, May 06, 2010 8:29:39 AM

Post# of 72979
May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

So....that's what it was...
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up